Literature DB >> 4031069

Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26.

G Salen, S Shefer, G S Tint, G Nicolau, B Dayal, A K Batta.   

Abstract

To examine the defect in side-chain oxidation during the formation of bile acids in cerebrotendinous xanthomatosis, we measured in vitro hepatic microsomal hydroxylations at C-12 and C-25 and mitochondrial hydroxylation at C-26 and related them to the pool size and synthesis rates of cholic acid and chenodeoxycholic acid as determined by the isotope dilution technique. Hepatic microsomes and mitochondria were prepared from seven subjects with cerebrotendinous xanthomatosis and five controls. Primary bile acid synthesis was markedly reduced in cerebrotendinous xanthomatosis as follows: cholic acid, 133 +/- 30 vs. 260 +/- 60 mg/d in controls; and chenodeoxycholic acid, 22 +/- 10 vs. 150 +/- 30 mg/d in controls. As postulated for chenodeoxycholic acid synthesis, mitochondrial 26-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha-diol was present in all specimens and was 30-fold more active than the corresponding microsomal 25-hydroxylation. However, mean mitochondrial 26-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha-diol was less active in cerebrotendinous xanthomatosis than in controls: 59 +/- 17 compared with 126 +/- 21 pmol/mg protein per min. As for cholic acid synthesis, microsomal 25-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol was substantially higher in cerebrotendinous xanthomatosis and control preparations (620 +/- 103 and 515 +/- 64 pmol/mg protein per min, respectively) than the corresponding control mitochondrial 26-hydroxylation of the same substrate (165 +/- 25 pmol/mg protein per min). Moreover in cerebrotendinous xanthomatosis, mitochondrial 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol-26-hydroxylase activity was one-seventh as great as in controls. Hepatic microsomal 12 alpha-hydroxylation, which may be rate-controlling for the cholic acid pathway, was three times more active in cerebrotendinous xanthomatosis than in controls: 1,600 vs. 500 pmol/mg protein per min. These results demonstrate severely depressed primary bile acid synthesis in cerebrotendinous xanthomatosis with a reduction in chenodeoxycholic acid formation and pool size disproportionately greater than that for cholic acid. The deficiency of chenodeoxycholic acid can be accounted for by hyperactive microsomal 12 alpha-hydroxylation that diverts precursors into the cholic acid pathway combined with decreased side-chain oxidation (mitochondrial 26-hydroxylation). However, side-chain oxidation in cholic acid biosynthesis may be initiated via microsomal 25-hydroxylation of 5beta-cholestane-3alpha,7alpha,12alpha-triol was substantially lower in control and cerebrotendinous xanthomatosis liver. Thus, separate mechanisms may exist for the cleavage of the cholesterol side chain in cholic acid and chenodeoxycholic acid biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031069      PMCID: PMC423892          DOI: 10.1172/JCI112030

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  The turnover of cholic acid in man: bile acids and steroids.

Authors:  S LINDSTEDT
Journal:  Acta Physiol Scand       Date:  1957-09-17

2.  Bile alcohol metabolism in man. Conversion of 5beta-cholestane-3alpha, 7alpha,12alpha, 25-tetrol to cholic acid.

Authors:  G Salen; S Shefer; T Setoguchi; E H Mosbach
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

3.  Identification of pentahydroxy bile alcohols in cerebrotendinous xanthomatosis: characterization of 5beta-cholestane-3alpha, 7alpha, 12alpha, 24xi, 25-pentol and 5beta-cholestane-3alpha, 7alpha, 12alpha, 23xi, 25-pentol.

Authors:  S Shefer; B Dayal; G S Tint; G Salen; E H Mosbach
Journal:  J Lipid Res       Date:  1975-07       Impact factor: 5.922

4.  Omega-hydroxylation of steriod side-chain in biosynthesis of bile acids.

Authors:  I Björkhem; J Gustafsson
Journal:  Eur J Biochem       Date:  1973-07-02

5.  Synthesis of 5beta-cholestane-3alpha, 7alpha, 12alpha, 25-tetrol and 5beta-cholestane-3alpha, 7alpha, 245, 25-pentol.

Authors:  B Dayal; S Shefer; G S Tint; G Salen; E H Mosbach
Journal:  J Lipid Res       Date:  1976-01       Impact factor: 5.922

6.  On the synthesis and metabolism of cholest-4-en-7-alpha-ol-3-one. Bile acids and steroids 156.

Authors:  I Björkhem; H Danielsson; C Issidorides; A Kallner
Journal:  Acta Chem Scand       Date:  1965

7.  Biosynthesis of bile acids in man. Hydroxylation of the C27-steroid side chain.

Authors:  I Björkhem; J Gustafsson; G Johansson; B Persson
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

8.  Studies on the 12alpha and 26-hydroxylation of bile alcohols by rabbit liver microsomes.

Authors:  G Nicolau; B I Cohen; G Salen; E H Mosbach
Journal:  Lipids       Date:  1976-02       Impact factor: 1.880

9.  The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.

Authors:  G Salen; S M Grundy
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  A biochemical abnormality in cerebrotendinous xanthomatosis. Impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain.

Authors:  T Setoguchi; G Salen; G S Tint; E H Mosbach
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

View more
  11 in total

Review 1.  Human CYP7A1 deficiency: progress and enigmas.

Authors:  Anne Beigneux; Alan F Hofmann; Stephen G Young
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings.

Authors:  M T Dotti; A Rufa; A Federico
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

3.  Case report 427: Cerebrotendinous xanthomatosis.

Authors:  M Burnstein; K A Buckwalter; W Martel; K D McClatchey; D Quint
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

4.  Anomalous enantioselectivity in the sharpless asymmetric dihydroxylation reaction of 24-nor-5beta-cholest-23-ene-3alpha,7alpha,12alpha-triol: synthesis of substrates for studies of cholesterol side-chain oxidation.

Authors:  N H Ertel; B Dayal; K Rao; G Salen
Journal:  Lipids       Date:  1999-04       Impact factor: 1.880

5.  Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis.

Authors:  A Mignarri; S Rossi; M Ballerini; G N Gallus; M Del Puppo; P Galluzzi; A Federico; M T Dotti
Journal:  J Neurol       Date:  2010-11-21       Impact factor: 4.849

6.  Demonstration of 26-hydroxylation of C27-steroids in human skin fibroblasts, and a deficiency of this activity in cerebrotendinous xanthomatosis.

Authors:  S Skrede; I Björkhem; E A Kvittingen; M S Buchmann; S O Lie; C East; S Grundy
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

7.  Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.

Authors:  M G M de Sain-van der Velden; A Verrips; B H C M T Prinsen; M de Barse; R Berger; G Visser
Journal:  J Inherit Metab Dis       Date:  2008-10-24       Impact factor: 4.982

8.  Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports.

Authors:  Maria Donata Di Taranto; Monica Gelzo; Carola Giacobbe; Marco Gentile; Gennaro Marotta; Silvia Savastano; Antonio Dello Russo; Giuliana Fortunato; Gaetano Corso
Journal:  Metab Brain Dis       Date:  2016-05-26       Impact factor: 3.584

9.  Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands.

Authors:  B J Koopman; B G Wolthers; J C van der Molen; W van der Slik; R J Waterreus; A van Spreeken
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

10.  Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor.

Authors:  Bryan Goodwin; Karine C Gauthier; Michihisa Umetani; Michael A Watson; Matthew I Lochansky; Jon L Collins; Eran Leitersdorf; David J Mangelsdorf; Steven A Kliewer; Joyce J Repa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.